IAM1363-01: A Phase 1/1b Study of a Selective and Brain-Penetrant HER2 Inhibitor for HER2-Driven Solid Tumors
Publications
This is some text inside of a div block.
June 1, 2024
Related announcements
Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors
Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors
Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer
